Clinical bottom line
Intravenous metoprolol is a viable option for acute rate control in patients presenting to the emergency department (ED) with atrial fibrillation and rapid ventricular response (RVR). Evidence from comparative studies and meta-analyses suggests that metoprolol offers similar efficacy to intravenous diltiazem in reducing heart rate, with some data indicating a potentially more favorable safety profile in certain patient subsets. However, variability in dosing strategies and patient characteristics warrants cautious interpretation. Early use of intravenous metoprolol may be considered as part of individualized management, especially when calcium channel blockers are contraindicated or poorly tolerated.
What the evidence shows
Several randomized and observational studies have compared intravenous metoprolol to diltiazem for acute rate control in atrial fibrillation with RVR in the ED setting. Demircan et al. (2005) demonstrated comparable effectiveness between metoprolol and diltiazem in achieving target heart rate reduction, with no significant difference in adverse events. More recent meta-analyses, such as Lan et al. (2022) and Bolton et al. (2023), pooled data from multiple trials and observational cohorts, confirming that both agents effectively reduce ventricular rate within the first hour of administration. These analyses found no consistent superiority in efficacy but noted that metoprolol may have a lower incidence of hypotension compared to diltiazem.
Burum et al. (2023) specifically reviewed weight-based dosing of intravenous metoprolol, highlighting that tailored dosing may optimize rate control while minimizing adverse effects. Medeiros et al. (2021) and Blackburn et al. (2023) further supported the safety and efficacy of metoprolol, emphasizing its utility in patients with unknown or reduced ejection fraction where calcium channel blockers might be less desirable.
DEMİR Mehmet Cihat et al. (2021) addressed the clinical challenge of rate control in patients with unknown left ventricular function, finding metoprolol to be a reasonable choice in this population. Hines et al. (2016) also compared these agents in the ED and found no significant difference in time to rate control or adverse events, reinforcing the interchangeable use of metoprolol and diltiazem in many clinical scenarios.
Caveats and uncertainty
The evidence base includes heterogeneous patient populations, varying dosing regimens, and differing definitions of successful rate control, which complicates direct comparisons. Most studies are limited by relatively small sample sizes and single-center designs. The impact of underlying cardiac function, comorbidities, and concurrent medications on outcomes remains incompletely characterized.
Notably, the safety profile of metoprolol in patients with acute heart failure or severe left ventricular dysfunction is less well established, and caution is advised given the negative inotropic effects of beta-blockers. The timing and dosing of intravenous metoprolol vary widely across studies, and optimal protocols for rapid and safe rate control require further clarification.
Additionally, while metoprolol may cause less hypotension, it can induce bronchospasm in susceptible patients, limiting its use in those with reactive airway disease. The choice between metoprolol and diltiazem should consider individual patient factors, including blood pressure, pulmonary status, and potential drug interactions.
How this may change practice
Emergency clinicians may consider intravenous metoprolol as a first-line agent for acute rate control in atrial fibrillation with RVR, particularly when calcium channel blockers are contraindicated or when hypotension is a concern. Weight-based dosing strategies may enhance efficacy and safety, but local protocols should be adapted based on available evidence and clinical judgment.
This evidence digest supports a flexible, patient-centered approach to rate control, encouraging clinicians to weigh the benefits and risks of metoprolol versus diltiazem in the ED. Further research into standardized dosing and comparative effectiveness in diverse populations will help refine practice guidelines.